Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | RXRB | P28702 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978502 | 0.93 | RAB9A (0.71) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL10236929 | 0.91 | RAB9A (0.82) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL11350421 | 0.91 | RAB9A (0.82) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL27395439 | 0.91 | RAB9A (0.68) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL9343582 | 0.89 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL6341485 | 0.89 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL898771 | 0.89 | RXRA (0.77) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL1122731 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL3729907 | 0.87 | NPC1 (0.75) | SMN1; SMN2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL12086470 | 0.87 | RAB9A (0.80) | SMN1; SMN2MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688743-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024206153-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2018019084-A1 | BENZAMIDE COMPOUND AND USE THEREOF IN PREPARING DRUGS INHIBITING CANCER CELL PROLIFERATION AND/OR TREATING CANCER | 北京化工大学 | 2018-02-01 | — | — | WO | disclosed |
| US-9856252-B2 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-01-02 | — | — | US | disclosed |
| EP-3077386-B1 | BENZHYDRYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2017-09-06 | — | — | EP | disclosed |
| EP-2958898-B1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2017-07-19 | — | — | EP | disclosed |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2016-08-04 | — | — | US | disclosed |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2016-08-04 | — | — | US | disclosed |
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-0677039-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5872138-A | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION IN A MAMMAL | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5783593-A | FUNGICIDE; ANTICHOLESTEROL AGENT | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| WO-1998010763-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5631401-A | Inhibitors of protein farnesyltransferase and squalene synthase | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996034850-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0677039-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0664316-A1 | Polycarbonate composition having improved resistance to gamma-ray radiation | TEIJIN LIMITED (JP) | 1995-07-26 | — | — | EP | disclosed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | B2M, HBG2, BCAT2 | SMN1; SMN2 1709/4885MEN1 2210/4885KMT2A 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.